FDA clears Ekso Bionics’ robotic exoskeleton for use with MS patients

[Image from Ekso Bionics]Ekso Bionics (Nasdaq:EKSO) announced today that it received FDA 510(k) clearance for its EksoNR robotic exoskeleton.

Richmond, California-based Ekso Bionics designed the EksoNR technology for use with Multiple Sclerosis (MS) patients.

According to a news release, EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use in patients with MS, significantly expanding the device’s use to a broader group of patients.

The latest generation of the Ekso Bionics platform, the EksoNR previously received clearance for stroke and spinal cord rehabilitation in 2016, then acquired brain injury (ABI) in 2020. Ekso said it was the first of its kind to receive a stroke indication and stands as the only exoskeleton with indications for ABI and now MS. EksoNR also has CE mark, the company said.

“As a leader in early-to-market wearable robotic solutions for medical rehabilitation, we are committed to maximizing…

Read more
  • 0